fda import alert glp-1 semaglutide tirzepatide green list Demurs on Compounding Fight, Debuts Consumer 'Green List' Instead HIMS Positioned Strongly Amid FDA
Description
In a randomized controlled trial, 52 healthy obese individuals were, after a diet-induced 12% body weight loss, randomized to treatment with or without administration of the GLP-1RA liraglutide (1.2mg per day)
Stopping GLP-1 prior to surgery requires careful planning due to delayed gastric emptying and aspiration risk
New evidence clarifies GLP-1 pancreatic cancer risk, reviewing long-term registry data and practical guidance for evidence-based patient counseling.
Tell your healthcare professional about all biotin-containing supplements before testing
Four-year data on the GLP-1 RA shows obesity and cardiovascular benefits are widespread and long term.
